Novartis Pharmaceuticals UK Ltd

Information

Name

Type

Company

Roles

Supplier

Company Size

Large

Company Number

Incorporation Date

Website

https://www.novartis.co.uk/

Address

Frimley Business Park, Frimley, Surrey

Frimley
GU16 7SR
United Kingdom

Suppliers

Unlock the full supplier list, free!

Sign up to unlock the full list of suppliers associated with Novartis Pharmaceuticals UK Ltd
Sign up free

Contracts awarded to Novartis Pharmaceuticals UK Ltd

The contracts that Novartis Pharmaceuticals UK Ltd have been awarded to supply. Click on the contract to view more detailed information and view the full details about the contract won.

Award

Published 2 months ago

Ustekinumab and Omalizumab

Supply of Ustekinumab and Omalizumab to NHS Scotland

£13,816,578
Award

Published 2 months ago

NHS National Framework for Medical Retinal Vascular Treatments 1 August 2024

roject title: CM/PHS/24/5707 NHS National Framework for Medical Retinal Vascular Treatments 1 August 2024 Period of framework: 1 August 2024 to 31 July 2025. with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months

£416,830,570 Bids close: 7 months ago
Award

Published 2 months ago

NHS Branded Medicines Tranche Framework for London and South of England

NHS Branded Medicines Tranche Framework for London and South of England - 1 September 2024 Offer reference number: CM/PHR/22/5689 CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South of England Tranche A. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South of England Tranche B. Period of framework: 1 September 2024 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/03 - NHS Framework for the supply of Omalizumab and Diroximel Fumarate for the Midlands & East and North of England. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

£380,950,720 Bids close: 7 months ago
Award

Published 2 months ago

NHS Branded Medicines Tranche Framework for London and South of England

NHS Branded Medicines Tranche Framework for London and South of England - 1 September 2024<br/>Offer reference number: CM/PHR/22/5689<br/>CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South of England Tranche A. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.<br/>CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South of England Tranche B. Period of framework: 1 September 2024 to 31 August 2026 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.<br/>CM/PHR/22/5689/03 - NHS Framework for the supply of Omalizumab and Diroximel Fumarate for the Midlands & East and North of England. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.

£39
Award

Published 2 months ago

Generic, Branded Generic & Proprietary Medicinal Products - Group 14

Generic, Branded Generic & Proprietary Medicinal Products - Group 14 (5190931)

£10,725,841
Award

Published 6 months ago

NHS Framework Agreement for Branded Medicines - National Tender - 1 May 2024

NHS Framework Agreement for Branded Medicines - National Tender - 1 May 2024 Offer reference number: CM/PHR/22/5682 CM/PHR/22/5682/01 - NHS Framework Agreement for Branded Medicines - National Tender - Lot 1. Period of framework: 1 May 2024 to 30 April 2028. CM/PHR/22/5682/02 - NHS Framework Agreement for Branded Medicines - National Tender - Lot 2. Period of framework: 1 May 2024 to 30 April 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

Bids close: 11 months ago

Contacts

+44 7879667600

Statistics (1 Year)

Contracts Won

Total Won

£24,542,419

Average Win

£12,271,210

Novartis Pharmaceuticals UK Ltd

Information

Name

Type

Roles

Company Size

Company Number

Incorporation Date

Website

Address

Suppliers

Contracts awarded to Novartis Pharmaceuticals UK Ltd

Ustekinumab and Omalizumab

NHS National Framework for Medical Retinal Vascular Treatments 1 August 2024

NHS Branded Medicines Tranche Framework for London and South of England

NHS Branded Medicines Tranche Framework for London and South of England

Generic, Branded Generic & Proprietary Medicinal Products - Group 14

NHS Framework Agreement for Branded Medicines - National Tender - 1 May 2024

Contacts

Statistics (1 Year)

Contracts Won

Total Won

Average Win